다이이찌산쿄(Daiichi Sankyo Company, Limited)는 일본, 미국, 유럽 및 전 세계에서 의약품을 제조 및 판매합니다. 이 회사는 HER2 양성 및 저발현 유방암, HER2 양성 위암 또는 위식도 접합부 선암, HER2 양성 고형암 환자 치료를 위한 Enhertu를 제공합니다. 또한 증상성 TGCT 치료를 위해 집락 자극 인자 1 수용체, KIT 원종양유전자 수용체 티로신 키나아제, 그리고 내부 직렬 중복 돌연변이를 가진 FMS 유사 티로신 키나아제 3을 표적으로 하는 경구용 저분자 화합물 Turalio
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment of symptomatic TGCT; Vanflyta, a FLT3 inhibitor to treat patients with acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and DATROWAY to treat adult patients with breast cancer and NSCLC. It also provides Liziana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo, an oral treatment that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia and Tenelia for the treatment of type 2 diabetes mellitus; Emgalty and Reyvow to treat migraine attacks; Pralia for the treatment of osteoporosis of the progression of bone erosion associated with rheumatoid arthritis; Ranmark to treat bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer to treat iron deficiency anemia; and Vimpat, an anti-seizure medication. Further, it provides vaccines for the treatment of COVID-19, influenza infections, adsorbed cell culture-derived influenza (H5N1) influenza infections, measles/rubella infections, and mumps infections. It has a strategic collaboration with Lunit Inc. for the development of biomarker discovery and optimize translational research. The company was founded in 1899 and is headquartered in Chuo, Japan.